featured
Future Perspectives and Challenges With CDK4/6 Inhibitors in HR+ Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Future Oncology (London, England)
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Future Perspectives and Challenges With CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer
Future Oncol 2020 Aug 17;[EPub Ahead of Print], S Bayraktar, S Batoo, E Al-Hattab, S Basu, S Okuno, S GlückFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.